This agent is a cyclin-dependent kinase inhibitor, which effectively induces ICD in exposed tumor cell lines, while demonstrating antitumor efficacy in murine models of experimental oncoimmunotherapy when used in combination with anti-PD-1 Mabs [121]. The gene discussed is PDCD1; the disease is neoplasm.